Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.
Mauldin IS, Wages NA, Stowman AM, Wang E, Smolkin ME, Olson WC, Deacon DH, Smith KT, Galeassi NV, Chianese-Bullock KA, Dengel LT, Marincola FM, Petroni GR, Mullins DW, Slingluff CL Jr. Mauldin IS, et al. Cancer Immunol Immunother. 2016 Oct;65(10):1189-99. doi: 10.1007/s00262-016-1881-y. Epub 2016 Aug 13. Cancer Immunol Immunother. 2016. PMID: 27522581 Free PMC article. Clinical Trial.
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64).
Vavolizza RD, Petroni GR, Mauldin IS, Chianese-Bullock KA, Olson WC, Smith KT, Dengel LT, Haden K, Grosh WW, Kaur V, Varhegyi N, Gaughan EM, Slingluff CL Jr. Vavolizza RD, et al. Among authors: mauldin is. J Immunother Cancer. 2022 Sep;10(9):e005424. doi: 10.1136/jitc-2022-005424. J Immunother Cancer. 2022. PMID: 36100309 Free PMC article. Clinical Trial.
A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.
Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Chianese-Bullock KA, Mauldin IS, Smith KT, Deacon DH, Varhegyi NE, Donnelly SB, Reed CM, Scott K, Galeassi NV, Grosh WW. Slingluff CL Jr, et al. Among authors: mauldin is. Cancer Immunol Immunother. 2016 Jan;65(1):25-36. doi: 10.1007/s00262-015-1770-9. Epub 2015 Nov 18. Cancer Immunol Immunother. 2016. PMID: 26581199 Free PMC article. Clinical Trial.
Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.
Mauldin IS, Wages NA, Stowman AM, Wang E, Olson WC, Deacon DH, Smith KT, Galeassi N, Teague JE, Smolkin ME, Chianese-Bullock KA, Clark RA, Petroni GR, Marincola FM, Mullins DW, Slingluff CL Jr. Mauldin IS, et al. Cancer Immunol Immunother. 2016 Oct;65(10):1201-12. doi: 10.1007/s00262-016-1880-z. Epub 2016 Aug 13. Cancer Immunol Immunother. 2016. PMID: 27522582 Free PMC article.
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Slingluff CL, Zarour HM, Tawbi HA, Kirkwood JM, Postow MA, Friedlander P, Devoe CE, Gaughan EM, Mauldin IS, Olson WC, Smith KT, Macri MJ, Ricciardi T, Ryan A, Venhaus R, Wolchok JD. Slingluff CL, et al. Among authors: mauldin is. Oncoimmunology. 2021 Mar 26;10(1):1898105. doi: 10.1080/2162402X.2021.1898105. Oncoimmunology. 2021. PMID: 33796406 Free PMC article. Clinical Trial.
Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.
Pollack KE, Meneveau MO, Melssen MM, Lynch KT, Koeppel AF, Young SJ, Turner S, Kumar P, Sol-Church K, Mauldin IS, Slingluff CL Jr. Pollack KE, et al. Among authors: mauldin is. J Immunother Cancer. 2020 Apr;8(1):e000544. doi: 10.1136/jitc-2020-000544. J Immunother Cancer. 2020. PMID: 32350119 Free PMC article.
24 results